Danish drugmaker Novo Nordisk’s anti-inflammatory antibody ziltivekimab and Swiss drugmaker Novartis’ lipoprotein(a)-lowering drug pelacarsen sharply reduced their targeted blood markers but failed to prevent major cardiovascular events, according to full Phase 3 results presented on November 7 at the American Heart Association’s Scientific Sessions.